Karyopharm extends debt forbearance period to November 1, 2026
No actual financial results were disclosed, so the filing cannot be compared with the prior FY 2026 guidance midpoint. The applicable parties extended the forbearance period under the September 10, 2026 Forbearance Agreement and Limited Waiver to Indentures from 11:59 p.m. Eastern time on October 22 to 11:59 p.m. Eastern time on November 1, 2026, absent earlier termination.
Key takeaways
Debt forbearance: The forbearance period was extended through 11:59 p.m. Eastern time on November 1, 2026.
Previous deadline: The applicable parties had extended the forbearance period to October 22, 2026.
Agreement: The forbearance and limited waiver relate to indentures and were documented in an agreement dated September 10, 2026.
Early termination: The November 1, 2026 end date applies absent an earlier termination of the Forbearance Period.
Financial guidance: The filing disclosed no actual results or updated FY 2026 guidance.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow KPTI in real time
Get material earnings, filing, IR, and earnings-call alerts by email.